Yong Zang

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	<scp>T3</scp> + 3: 3 + 3 Design With Delayed Outcomes	2024	Jiaying Guo Mengyi Lu Isabella Wan Yu‐Min Wang Leng Han Yong Zang
+ PDF Chat	A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison	2024	Yong Zang Peter F. Thall Ying Yuan
+	Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies	2024	Yong Zang Beibei Guo Yingjie Qiu Hao Liu Mateusz Opyrchal Xiongbin Lu
+	Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes	2023	Peter F. Thall Yong Zang Andrew G. Chapple Ying Yuan Ruitao Lin David Marín Pavlos Msaouel
+	Generalized phase <scp>I‐II</scp> designs to increase long term therapeutic success rate	2023	Peter F. Thall Yong Zang Ying Yuan
+ PDF Chat	Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose	2023	Yingjie Qiu Yi Zhao Hao Liu Sha Cao Chi Zhang Yong Zang
+ PDF Chat	Component-Wise Adaptive Trimming For Robust Mixture Regression	2023	Wennan Chang Xinyu Zhou Yue Fang Yong Zang Chi Zhang Sha Cao
+	A Bayesian phase I/<scp>II</scp> design to determine <scp>subgroup‐specific</scp> optimal dose for immunotherapy sequentially combined with radiotherapy	2022	Beibei Guo Yong Zang Li‐Hsiang Lin Rui Zhang
+ PDF Chat	Spatially and Robustly Hybrid Mixture Regression Model for Inference of Spatial Dependence	2021	Wennan Chang Pengdao Dang Changlin Wan Xiaoyu Lu Yue Fang Tong Zhao Yong Zang Bo Li Chi Zhang Sha Cao
+	BIPSE: A biomarker‐based phase I/II design for immunotherapy trials with progression‐free survival endpoint	2021	Beibei Guo Yong Zang
+	Spatially and Robustly Hybrid Mixture Regression Model for Inference of Spatial Dependence	2021	Wennan Chang Pengtao Dang Changlin Wan Xiaoyu Lu Yue Fang Tong Zhao Yong Zang Bo Li Chi Zhang Sha Cao
+	BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time-to-event efficacy	2020	Beibei Guo Yong Zang
+	<scp>TSNP</scp>: A <scp>two‐stage</scp> nonparametric phase I/<scp>II</scp> clinical trial design for immunotherapy	2020	Yan Han Hao Liu Sha Cao Chi Zhang Yong Zang
+ PDF Chat	Supervised clustering of high-dimensional data using regularized mixture modeling	2020	Wennan Chang Changlin Wan Yong Zang Chi Zhang Sha Cao
+ PDF Chat	BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time‐to‐event efficacy	2020	Beibei Guo Yong Zang
+	A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes	2020	Yifei Zhang Sha Cao Chi Zhang Ick Hoon Jin Yong Zang
+	A New Algorithm using Component-wise Adaptive Trimming For Robust Mixture Regression.	2020	Wennan Chang Xinyu Zhou Yong Zang Chi Zhang Sha Cao
+ PDF Chat	A Bayesian adaptive marker‐stratified design for molecularly targeted agents with customized hierarchical modeling	2019	Yong Zang Beibei Guo Yan Han Sha Cao Chi Zhang
+ PDF Chat	A Bayesian adaptive phase II clinical trial design accounting for spatial variation	2018	Beibei Guo Yong Zang
+	A Bayesian adaptive phase II clinical trial design accounting for spatial variation	2018	Beibei Guo Yong Zang
+	A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials	2017	Yong Zang J. Jack Lee
+ PDF Chat	A robust two‐stage design identifying the optimal biological dose for phase I/II clinical trials	2016	Yong Zang J. Jack Lee
+ PDF Chat	Optimal marker-strategy clinical trial design to detect predictive markers for targeted therapy	2016	Yong Zang Suyu Liu Ying Yuan
+ PDF Chat	Two-Stage Marker-Stratified Clinical Trial Design in the Presence of Biomarker Misclassification	2016	Yong Zang J. Jack Lee Ying Yuan
+	Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkers	2016	Yong Zang Ying Yuan
+	Optimal two-stage enrichment design correcting for biomarker misclassification	2015	Yong Zang Beibei Guo
+	Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers	2014	Yong Zang Suyu Liu Ying Yuan
+	Adaptive clinical trial designs in oncology.	2014	Yong Zang J. Jack Lee
+ PDF Chat	A Shrinkage Method for Testing the Hardy–Weinberg Equilibrium in Case‐Control Studies	2013	Yong Zang Ying Yuan
+	Simple Algorithms to Calculate Asymptotic Null Distributions of Robust Tests in Case-Control Genetic Association Studies in R	2010	Wing K. Fung Yong Zang Gang Zheng
+	Asymptotic powers for matched trend tests and robust matched trend tests in case-control genetic association studies	2009	Yong Zang Wing K. Fung Gang Zheng
+	Tail Strength to Combine Two p Values: Their Correlation Cannot Be Ignored	2009	Yong Zang Wing K. Fung Gang Zheng

Common Coauthors

Coauthor	Papers Together
Sha Cao	9
Beibei Guo	9
Ying Yuan	8
Wennan Chang	5
J. Jack Lee	4
Peter F. Thall	3
Chi Zhang	3
Gang Zheng	3
Changlin Wan	3
Yue Fang	3
Wing K. Fung	3
Hao Liu	2
Xiaoyu Lu	2
Xinyu Zhou	2
Yan Han	2
Chi Zhang	2
Yingjie Qiu	2
Suyu Liu	2
Chi Zhang	1
Chi Zhang	1
Yi Zhao	1
Hao Liu	1
Yu‐Min Wang	1
Chi Zhang	1
Jiaying Guo	1
Leng Han	1
Yifei Zhang	1
Tong Zhao	1
Rui Zhang	1
Pengdao Dang	1
David Marín	1
Tong Zhao	1
Pengtao Dang	1
Ick Hoon Jin	1
Chi Zhang	1
Ruitao Lin	1
Andrew G. Chapple	1
Li‐Hsiang Lin	1
Mengyi Lu	1
Mateusz Opyrchal	1
Pavlos Msaouel	1
Xiongbin Lu	1
Isabella Wan	1
Bo Li	1
Bo Li	1
Yifei Zhang	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs	2004	Peter F. Thall John D. Cook	10
+ PDF Chat	Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities	2000	Ying Kuen Cheung Rick Chappell	8
+	The bivariate continual reassessment method	2002	Thomas M. Braun	8
+	A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials	1998	Peter F. Thall Kathy Russell	8
+	Bayesian Phase I/II Biomarker-Based Dose Finding for Precision Medicine With Molecularly Targeted Agents	2016	Beibei Guo Ying Yuan	8
+	Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer	1990	John O’Quigley Margaret S. Pepe Lloyd D. Fisher	7
+	An adaptive dose-finding design incorporating both toxicity and efficacy	2005	Wei Zhang Daniel J. Sargent Sumithra J. Mandrekar	7
+ PDF Chat	Adaptive designs for identifying optimal biological dose for molecularly targeted agents	2014	Yong Zang J. Jack Lee Ying Yuan	7
+ PDF Chat	A Bayesian Phase I/II Trial Design for Immunotherapy	2017	Suyu Liu Beibei Guo Ying Yuan	7
+ PDF Chat	Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges	2009	Sumithra J. Mandrekar Daniel J. Sargent	7
+	Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials	2005	Daniel J. Sargent Barbara A. Conley Carmen J. Allegra Laurence Collette	6
+ PDF Chat	Robust EM Continual Reassessment Method in Oncology Dose Finding	2011	Ying Yuan Guosheng Yin	6
+ PDF Chat	Using Data Augmentation to Facilitate Conduct of Phase I–II Clinical Trials With Delayed Outcomes	2014	Ick Hoon Jin Suyu Liu Peter F. Thall Ying Yuan	6
+	Bayesian Designs for Phase I–II Clinical Trials	2017	Ying Yuan Hoang Q. Nguyen Peter F. Thall	6
+	Design and Analysis of Phase I Clinical Trials	1989	Barry E. Storer	6
+	Bayesian Dose‐Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios	2006	Guosheng Yin Yisheng Li Yuan Ji	6
+ PDF Chat	On the efficiency of targeted clinical trials	2004	A. Maitournam Richard Simon	5
+ PDF Chat	Bayesian adaptive randomization designs for targeted agent development	2010	J. Jack Lee Xuemin Gu Suyu Liu	5
+ PDF Chat	Bayesian phase I/II adaptively randomized oncology trials with combined drugs	2011	Ying Yuan Guosheng Yin	5
+ PDF Chat	Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials	2004	Richard Simon Aboubakar Maitournam	5
+ PDF Chat	BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies	2020	Ruitao Lin Yanhong Zhou Fangrong Yan Daniel Li Ying Yuan	4
+ PDF Chat	Dose Escalation Methods in Phase I Cancer Clinical Trials	2009	Christophe Le Tourneau J. Jack Lee Lillian L. Siu	4
+	Finite Mixture and Markov Switching Models	2006	Sylvia Frühwirth‐Schnatter	4
+	Maximum Likelihood from Incomplete Data Via the <i>EM</i> Algorithm	1977	A. P. Dempster N. M. Laird Donald B. Rubin	4
+	Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity	2013	Suyu Liu Guosheng Yin Ying Yuan	4
+	A utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies	2019	Yanhong Zhou J. Jack Lee Ying Yuan	4
+ PDF Chat	Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes	2013	Peter F. Thall Hoang Q. Nguyen Thomas M. Braun Muzaffar H. Qazilbash	4
+	A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes	2020	Yifei Zhang Sha Cao Chi Zhang Ick Hoon Jin Yong Zang	4
+ PDF Chat	Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents	2010	Antje Hoering Mike LeBlanc John Crowley	4
+ PDF Chat	A new method for robust mixture regression	2016	Chun Yu Weixin Yao Kun Chen	4
+ PDF Chat	A robust two‐stage design identifying the optimal biological dose for phase I/II clinical trials	2016	Yong Zang J. Jack Lee	4
+ PDF Chat	Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding	2017	Fangrong Yan Peter F. Thall K.H. Lu Mark R. Gilbert Ying Yuan	4
+ PDF Chat	A robust Bayesian dose-finding design for phase I/II clinical trials	2015	Suyu Liu Valen E. Johnson	4
+ PDF Chat	Bayesian optimal interval designs for phase I clinical trials	2014	Suyu Liu Ying Yuan	4
+ PDF Chat	Optimizing Natural Killer Cell Doses for Heterogeneous Cancer Patients on the Basis of Multiple Event Times	2018	Juhee Lee Peter F. Thall Katy Rezvani	4
+	Bayesian sequential monitoring designs for single‐arm clinical trials with multiple outcomes	1995	Peter F. Thall Richard Simon Elihu H. Estey	3
+	None	2000	David Peel Geoffrey J. McLachlan	3
+ PDF Chat	A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents	2013	Chunyan Cai Ying Yuan Yuan Ji	3
+ PDF Chat	Phase II Trial Design with Bayesian Adaptive Randomization and Predictive Probability	2012	Guosheng Yin Nan Chen J. Jack Lee	3
+ PDF Chat	Robust mixture regression model fitting by Laplace distribution	2013	Weixing Song Weixin Yao Yanru Xing	3
+	Sampling-Based Approaches to Calculating Marginal Densities	1990	Alan E. Gelfand A. F. M. Smith	3
+	Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers	2014	Yong Zang Suyu Liu Ying Yuan	3
+	Incomplete Data in Generalized Linear Models	1990	Joseph G. Ibrahim	3
+ PDF Chat	Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy as Time-to-Event Outcomes	2009	Ying Yuan Guosheng Yin	3
+	An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations	2006	Sumithra J. Mandrekar Yue Cui Daniel J. Sargent	3
+ PDF Chat	An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics	2010	Patricia LoRusso Scott A. Boerner Lesley Seymour	3
+ PDF Chat	Utility‐Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials	2009	Nadine Houedé Peter F. Thall Hoang Q. Nguyen Xavier Paolettí Andrew Kramar	3
+ PDF Chat	Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice	2004	Wendy R. Parulekar Elizabeth A. Eisenhauer	3
+	Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials	2009	Guosheng Yin Ying Yuan	3
+ PDF Chat	Robust fitting of mixture regression models	2012	Xiuqin Bai Weixin Yao John E. Boyer	3